Delphi Consensus for decision-making in preventive treatments for migraine

What did Adelphi Targis provide?

Our client had just placed a new biological on the market for the preventive treatment of chronic migraine.

The existing clinical guidelines defined when a preventive treatment for migraine should be initiated. However, the criteria for defining treatment effectiveness and decision-making with regard to treatment continuation were not clearly defined.

We defined a European Delphi study involving the participation of 148 health professionals specialising in migraine from five different countries, identifying the relevant factors to guide clinicians in taking decisions related to the continuation of preventive treatment for migraine.

Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My-LIFE European Delphi survey

Do you want to start up a project?

To top

C/ Aragó 182,  7th floor
08011 Barcelona - Spain
+34 93 452 39 11
This email address is being protected from spambots. You need JavaScript enabled to view it.